Single‐institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting

Abstract

BACKGROUND: Ipilimumab is a monoclonal antibody that antagonizes cytotoxic T lymphocyte antigen‐4, a negative regulator of the immune system. The authors report on advanced refractory melanoma patients treated in a compassionate use trial of ipilimumab at the Memorial Sloan‐Kettering Cancer Center. METHODS: Patients with advanced refractory melanoma were treated in a compassionate use trial with ipilimumab 10 mg/kg every 3 weeks for 4 doses. Those with evidence of clinical benefit at Week 24 (complete response [CR], partial response [PR], or stable disease [SD]) then received ipilimumab every 12 weeks. RESULTS: A total of 53 patients were enrolled, with 51 evaluable. Grade 3/4 immune‐related adverse events were noted in 29% of patients, with the most common immune‐related adverse events being pruritus (43%), rash (37%), and diarrhea (33%). On the basis of immune‐related response criteria, the response rate (CR + PR) was 12% (95% confidence interval [CI], 5%‐25%), whereas 29% had SD (95% CI, 18%‐44%). The median progression‐free survival was 2.6 months (95% CI, 2.3‐5.2 months), whereas the median overall survival (OS) was 7.2 months (95% CI, 4.0‐13.3 months). Patients with an absolute lymphocyte count (ALC) ≥1000/μL after 2 ipilimumab treatments (Week 7) had a significantly improved clinical benefit rate (51% vs 0%; P = .01) and median OS (11.9 vs 1.4 months; P < .001) compared with those with an ALC <1000/μL. CONCLUSIONS: The results confirm that ipilimumab is clinically active in patients with advanced refractory melanoma. The ALC after 2 ipilimumab treatments appears to correlate with clinical benefit and OS, and should be prospectively validated. Cancer 2010. © 2010 American Cancer Society.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 28

1. 1.

   American Cancer Society.

   Not in our library

2. 2.

   Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17:2105-2116.

   Not in our library10.1200/jco.1999.17.7.2105

3. 3.

   Eigentler TK, Caroli UM, Radny P, Garbe C. Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol. 2003;4:748-759.

   Not in our library10.1016/s1470-2045(03)01280-4

4. 4.

   Chapman PB, Einhorn LH, Meyers ML, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol. 1999;17:2745-2751.

   Not in our library10.1200/jco.1999.17.9.2745

5. 5.

   Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med. 1995;182:459-465.

   Not in our library10.1084/jem.182.2.459

6. 6.

   Salomon B, Lenschow DJ, Rhee L, et al. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity. 2000;12:431-440.

   Not in our library10.1016/s1074-7613(00)80195-8

7. 7.

   Walunas TL, Bakker CY, Bluestone JA. CTLA-4 ligation blocks CD28-dependent T cell activation. J Exp Med. 1996;183:2541-2550.

   Not in our library10.1084/jem.183.6.2541

8. 8.

   Brunner MC, Chambers CA, Chan FK, Hanke J, Winoto A, Allison JP. CTLA-4-mediated inhibition of early events of T cell proliferation. J Immunol. 1999;162:5813-5820.

   Not in our library

9. 9.

   Karandikar NJ, Vanderlugt CL, Walunas TL, Miller SD, Bluestone JA. CTLA-4: a negative regulator of autoimmune disease. J Exp Med. 1996;184:783-788.

   Not in our library10.1084/jem.184.2.783

10. 10.

    van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med. 1999;190:355-366.

    Not in our library10.1084/jem.190.3.355

11. 11.

    Maker AV, Attia P, Rosenberg SA. Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J Immunol. 2005;175:7746-7754.

    Not in our library10.4049/jimmunol.175.11.7746

12. 12.

    Quezada SA, Peggs KS, Curran MA, Allison JP. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest. 2006;116:1935-1945.

    Not in our library10.1172/jci27745

13. 13.

    Quezada SA, Peggs KS, Simpson TR, Shen Y, Littman DR, Allison JP. Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma. J Exp Med. 2008;205:2125-2138.

    Not in our library10.1084/jem.20080099

14. 14.

    Hodi FS, Mihm MC, Soiffer RJ, et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A. 2003;100:4712-4717.

    Not in our library10.1073/pnas.0830997100

15. 15.

    Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A. 2003;100:8372-8377.

    Not in our library10.1073/pnas.1533209100

16. 16.

    Beck KE, Blansfield JA, Tran KQ, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol. 2006;24:2283-2289.

    Not in our library10.1200/jco.2005.04.5716

17. 17.

    Hodi F, Hoos A, Ibrahim R, et al. Novel efficacy criteria for antitumor activity to immunotherapy using the example of ipilimumab, an anti-CTLA-4 monoclonal antibody. J Clin Oncol. 2008;26(15 suppl):3008.

    Not in our library

18. 18.

    Wolchok J, Ibrahim R, DePril V, et al. Antitumor response and new lesions in advanced melanoma patients on ipilimumab treatment. J Clin Oncol. 2008;26(15 suppl):3020.

    Not in our library

19. 19.

    Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. J Clin Oncol. 1983;1:710-719.

    Not in our library10.1200/jco.1983.1.11.710

20. 20.

    Hamid O, Chin K, Li J, et al. Dose effect of ipilimumab in patients with advanced melanoma: results from a phase II, randomized, dose-ranging study. J Clin Oncol. 2008;26(15 suppl):9025.

    Not in our library

21. 21.

    O'Day S, Ibrahim R, DePril V, et al. Efficacy and safety of ipilimumab induction and maintenance dosing in patients with advanced melanoma who progressed on 1 or more prior therapies. J Clin Oncol. 2008;26(15 suppl):9021.

    Not in our library

22. 22.

    Weber J, Berman D, Siegel J, et al. Safety and efficacy of ipilimumab with or without prophylactic budesonide in treatment-naive and previously treated patients with advanced melanoma. J Clin Oncol. 2008;26(15 suppl):9010.

    Not in our library

23. 23.

    Camacho LH, Antonia S, Sosman J, et al. Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol. 2009;27:1075-1081.

    Not in our library10.1200/jco.2008.19.2435

24. 24.

    Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol. 2000;18:158-166.

    Not in our library10.1200/jco.2000.18.1.158

25. 25.

    Attia P, Phan GQ, Maker AV, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol. 2005;23:6043-6053.

    Not in our library10.1200/jco.2005.06.205

26. 26.

    Downey SG, Klapper JA, Smith FO, et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res. 2007;13(22 pt 1):6681-6688.

    Not in our library10.1158/1078-0432.ccr-07-0187

27. 27.

    Weber JS, O'Day S, Urba W, et al. Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol. 2008;26:5950-5956.

    Not in our library10.1200/jco.2008.16.1927

28. 28.

    Berman D, Wolchok J, Weber J, Hamid O, O'Day S, Chasalow S. Association of peripheral blood absolute lymphocyte count (ALC) and clinical activity in patients (pts) with advanced melanoma treated with ipilimumab. J Clin Oncol. 2008;27(15 suppl):3020.

    Not in our library

Cited by papers we hold 15

• Tim-3/galectin-9 pathway and mMDSC control primary and secondary resistances to PD-1 blockade in lung cancer patients · 2019
  Not checked
• The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients · 2019
  No notice
• Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung Cancer patients treated with anti-PD-1 antibodies · 2018
  No notice
• Combining Immunotherapy and Radiotherapy for Cancer Treatment: Current Challenges and Future Directions · 2018
  No notice
• Predictors of responses to immune checkpoint blockade in advanced melanoma · 2017
  No notice
• Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors · 2017
  No notice
• Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers · 2017
  No notice
• Validation of biomarkers to predict response to immunotherapy in cancer: Volume I — pre-analytical and analytical validation · 2016
  No notice
• Novel technologies and emerging biomarkers for personalized cancer immunotherapy · 2016
  No notice
• Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy · 2016
  No notice
• Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal Melanoma · 2015
  No notice
• PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma · 2015
  No notice
• Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis · 2015
  No notice
• Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice · 2015
  No notice
• The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network · 2013
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.